GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed Price. Currency in GBp
1,654.50-7.50 (-0.45%)
As of 11:11 AM EDT. Market open.
People also watch:
BP.LAZN.LRDSB.LVOD.LULVR.L
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1,661.00
Prev Close1,662.00
Bid1,654.00 x 175400
Ask1,654.50 x 417900
Day's Range1,652.12 - 1,676.18
52wk Range1,227.50 - 1,716.50
1y Target EstN/A
Market Cap80.16B
P/E Ratio (ttm)2,757.50
BetaN/A
Volume2,379,734
Avg Vol (3m)8,690,993
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlaxoSmithKline Plc :GSK-GB: Earnings Analysis: Q2, 2016 By the Numbers : August 23, 2016
    Capital Cubeyesterday

    GlaxoSmithKline Plc :GSK-GB: Earnings Analysis: Q2, 2016 By the Numbers : August 23, 2016

    Categories: Yahoo Finance Get free summary analysis GlaxoSmithKline Plc reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of GlaxoSmithKline Plc – AstraZeneca PLC, Shire PLC and GW Pharmaceuticals PLC (AZN-GB, SHP-GB and GWP-GB) that have also reported for this period. Highlights Summary numbers: Revenues of GBP 6532 ... Read more (Read more...)

  • 3 High-Yielding Healthcare Stocks I'm Not Buying
    Motley Fool4 days ago

    3 High-Yielding Healthcare Stocks I'm Not Buying

    Computer Programs & Systems, GlaxoSmithKline, and AstraZeneca's high dividend yields aren't as alluring as some might think.

  • Zacks7 days ago

    Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study

    GlaxoSmithKline (GSK) announced that its HIV-focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two-drug regimen of Tivicay and Epivir for the treatment for HIV-1 infection.